FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178156522> ?p ?o ?g. }

• W3178156522 endingPage "1788" @default.
• W3178156522 startingPage "1788" @default.
• W3178156522 abstract "Abstract IL-12 is a cytokine produced by antigen-presenting cells that increases T cell proliferation, IFN gamma mediated Th1 effector functions and T and NK cell cytotoxicity. While these effects generate potent anti-tumor immunity in mouse models, the high toxicity of IL-12 in cancer patients has limited its clinical utility. Potency attenuation and intratumoral cytokine localization may improve IL-12 tolerability, but these approaches can reduce efficacy or be limited by intratumoral delivery or tumor antigen expression. To improve both tolerability and efficacy of IL-12, we engineered IL-12Fc fusions with anti-IL-12 antibodies to block IL-12 potency. Using linkers designed to be cleaved by highly active intratumoral proteases, blocking antibodies are released specifically in the tumor microenvironment, thereby increasing intratumoral IL-12 activity. Single chain IL-12 was fused to one C-termini of an Azymetric™ Fc heterodimer. To the other Fc C-termini, an anti-IL-12 scFv was fused via a protease-cleavable linker in order to block IL-12 activity. In addition to antibody blockade, modifications of IL-12Fc fusions were used to further limit IL-12Fc activity. In vitro potency was determined by CD8T cell IFN gamma release. Anti-IL-12 scFv cleavage in the presence of recombinant enzyme or human tumor material was assessed by reducing CE-SDS and LC/MS, respectively. All IL-12Fc fusions were produced with favorable biophysical characteristics. Modified IL-12Fc molecules had up to 500x reduced potency, while antibody blocked IL-12Fc molecules had up to 100,000x reduced potency compared to IL-12Fc control. In vitro cleavage of the anti-IL-12 scFv from IL-12Fc recovered potency to that of the corresponding non-masked IL-12Fc molecules. Reducing CE-SDS confirmed that anti-IL-12 scFvs were cleaved from IL-12Fc in the presence of recombinant enzyme. Cleavage of anti-IL-12 scFvs also occurred when variants were incubated in pancreatic tumor cell supernatant or human tumor tissue lysate. These results indicate that antibody blockade and re-activation by protease cleavage is a promising strategy to localize the activity of IL-12 to the tumor microenvironment while potentially limiting off-tumor toxicities. Further modifying antibody blocked IL-12 has the potential to better fine tune therapeutic index. We are pursuing tumor-specific IL-12 fusions for clinical application in tumors with high intratumoral protease activity. Citation Format: Jennifer Leah Bishop, Ryan Blackler, Gesa Volkers, Maya Poffenberger, Irene Yu, Joel Smith, Akram Khodabandehloo, Sifa Arrafi, Desmond Lau, Liz Stangle, Leisa Stenberg, Patricia Zwierzchowski, Iulia Dude, David Douda, Grant Wickman, Jeff Proctor, Gerry Rowse, Laurence Madera, Genevieve Desjardins, Nicole Afacan, Stuart Barnscher, David Mills, Thomas Spreter, Surjit Dixit. Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1788." @default.
• W3178156522 created "2021-07-19" @default.
• W3178156522 creator A5000722037 @default.
• W3178156522 creator A5004297204 @default.
• W3178156522 creator A5016309841 @default.
• W3178156522 creator A5016563792 @default.
• W3178156522 creator A5021600269 @default.
• W3178156522 creator A5032412967 @default.
• W3178156522 creator A5032740931 @default.
• W3178156522 creator A5032891902 @default.
• W3178156522 creator A5034659490 @default.
• W3178156522 creator A5036675776 @default.
• W3178156522 creator A5041816117 @default.
• W3178156522 creator A5044186049 @default.
• W3178156522 creator A5048503875 @default.
• W3178156522 creator A5052876240 @default.
• W3178156522 creator A5062606621 @default.
• W3178156522 creator A5066846450 @default.
• W3178156522 creator A5069995028 @default.
• W3178156522 creator A5070372219 @default.
• W3178156522 creator A5070397259 @default.
• W3178156522 creator A5070928275 @default.
• W3178156522 creator A5071695878 @default.
• W3178156522 creator A5082604651 @default.
• W3178156522 creator A5087002295 @default.
• W3178156522 creator A5090072380 @default.
• W3178156522 date "2021-07-01" @default.
• W3178156522 modified "2023-09-27" @default.
• W3178156522 title "Abstract 1788: Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation" @default.
• W3178156522 doi "https://doi.org/10.1158/1538-7445.am2021-1788" @default.
• W3178156522 hasPublicationYear "2021" @default.
• W3178156522 type Work @default.
• W3178156522 sameAs 3178156522 @default.
• W3178156522 citedByCount "2" @default.
• W3178156522 countsByYear W31781565222023 @default.
• W3178156522 crossrefType "journal-article" @default.
• W3178156522 hasAuthorship W3178156522A5000722037 @default.
• W3178156522 hasAuthorship W3178156522A5004297204 @default.
• W3178156522 hasAuthorship W3178156522A5016309841 @default.
• W3178156522 hasAuthorship W3178156522A5016563792 @default.
• W3178156522 hasAuthorship W3178156522A5021600269 @default.
• W3178156522 hasAuthorship W3178156522A5032412967 @default.
• W3178156522 hasAuthorship W3178156522A5032740931 @default.
• W3178156522 hasAuthorship W3178156522A5032891902 @default.
• W3178156522 hasAuthorship W3178156522A5034659490 @default.
• W3178156522 hasAuthorship W3178156522A5036675776 @default.
• W3178156522 hasAuthorship W3178156522A5041816117 @default.
• W3178156522 hasAuthorship W3178156522A5044186049 @default.
• W3178156522 hasAuthorship W3178156522A5048503875 @default.
• W3178156522 hasAuthorship W3178156522A5052876240 @default.
• W3178156522 hasAuthorship W3178156522A5062606621 @default.
• W3178156522 hasAuthorship W3178156522A5066846450 @default.
• W3178156522 hasAuthorship W3178156522A5069995028 @default.
• W3178156522 hasAuthorship W3178156522A5070372219 @default.
• W3178156522 hasAuthorship W3178156522A5070397259 @default.
• W3178156522 hasAuthorship W3178156522A5070928275 @default.
• W3178156522 hasAuthorship W3178156522A5071695878 @default.
• W3178156522 hasAuthorship W3178156522A5082604651 @default.
• W3178156522 hasAuthorship W3178156522A5087002295 @default.
• W3178156522 hasAuthorship W3178156522A5090072380 @default.
• W3178156522 hasConcept C109316439 @default.
• W3178156522 hasConcept C147483822 @default.
• W3178156522 hasConcept C153911025 @default.
• W3178156522 hasConcept C159654299 @default.
• W3178156522 hasConcept C181199279 @default.
• W3178156522 hasConcept C182220744 @default.
• W3178156522 hasConcept C185592680 @default.
• W3178156522 hasConcept C202751555 @default.
• W3178156522 hasConcept C203014093 @default.
• W3178156522 hasConcept C2776107976 @default.
• W3178156522 hasConcept C2777701055 @default.
• W3178156522 hasConcept C2778690821 @default.
• W3178156522 hasConcept C2780674031 @default.
• W3178156522 hasConcept C502942594 @default.
• W3178156522 hasConcept C55493867 @default.
• W3178156522 hasConcept C57992300 @default.
• W3178156522 hasConcept C86803240 @default.
• W3178156522 hasConcept C8891405 @default.
• W3178156522 hasConceptScore W3178156522C109316439 @default.
• W3178156522 hasConceptScore W3178156522C147483822 @default.
• W3178156522 hasConceptScore W3178156522C153911025 @default.
• W3178156522 hasConceptScore W3178156522C159654299 @default.
• W3178156522 hasConceptScore W3178156522C181199279 @default.
• W3178156522 hasConceptScore W3178156522C182220744 @default.
• W3178156522 hasConceptScore W3178156522C185592680 @default.
• W3178156522 hasConceptScore W3178156522C202751555 @default.
• W3178156522 hasConceptScore W3178156522C203014093 @default.
• W3178156522 hasConceptScore W3178156522C2776107976 @default.
• W3178156522 hasConceptScore W3178156522C2777701055 @default.
• W3178156522 hasConceptScore W3178156522C2778690821 @default.
• W3178156522 hasConceptScore W3178156522C2780674031 @default.
• W3178156522 hasConceptScore W3178156522C502942594 @default.
• W3178156522 hasConceptScore W3178156522C55493867 @default.
• W3178156522 hasConceptScore W3178156522C57992300 @default.
• W3178156522 hasConceptScore W3178156522C86803240 @default.
• W3178156522 hasConceptScore W3178156522C8891405 @default.
• W3178156522 hasIssue "13_Supplement" @default.
• W3178156522 hasLocation W31781565221 @default.

• next